You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 35 No. 1, January 1978 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Dopamine Excretion and Vulnerability to Drug-Induced Parkinsonism

Schizophrenic Patients

Thomas J. Crowley, MD; Margaret M. Hoehn, MD; Charles O. Rutledge, PhD; Mary Ann Stallings, RN, MS; Robert K. Heaton, PhD; Seymour Sundell, MD; Donald Stilson, PhD

Arch Gen Psychiatry. 1978;35(1):97-104.


Abstract

• Before and during a standardized course of trifluoperazine therapy, 18 schizophrenic patients underwent repeated examinations for extrapyramidal motor signs, clinical psychopathology, and urinary excretion of free and conjugated forms of dopamine and its metabolites. Patients excreting more free dopamine and metabolites, or showing less complete conjugation, before drug treatment, were much less likely than others to develop parkinsonian akinesia and rigidity during drug treatment. Neither catatonic rigidity nor akinesia before treatment was predictive of a parkinsonian response to trifluoperazine, but pretreatment tremor may have been. The severity of schizophrenic psychopathology was unrelated to dopamine excretion. This study of schizophrenic patients, and our previous research in Parkinson's disease, suggest that urinary dopamine excretion may reflect dopaminergic function of the extrapyramidal motor system in both conditions.



Author Affiliations

From the Departments of Psychiatry (Drs Crowley, Heaton, Sundell, and Stilson and Ms Stallings), Neurology (Dr Hoehn), and Pharmacology (Dr Rutledge), University of Colorado Medical Center, Denver. Dr Rutledge is now with the Department of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, Lawrence. Dr Sundell is now with the Denver Manager of Safety and Denver General Hospital.


Footnotes

Accepted for publication June 20, 1977.

Read in part before the annual meeting of the American Psychiatric Association, Toronto, May 4, 1977.

Reprint requests to Department of Psychiatry, University of Colorado Medical Center, 4200 E Ninth Ave, Denver, CO 80220 (Dr Crowley).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Motility, Parkinsonism, and Prolactin With Thiothixene and Thioridazine
Crowley and Hydinger-Macdonald
Arch Gen Psychiatry 1981;38:668-675.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1978 American Medical Association. All Rights Reserved.